Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

NINDS Hemicrania Continua Information Page


Table of Contents (click to jump to sections)


Listen to this page using ReadSpeaker


What is Hemicrania Continua?

Hemicrania continua is a chronic and persistent form of headache marked by continuous pain that varies in severity, always occurs on the same side of the face and head, and is superimposed with additional debilitating symptoms.  on the continuous but fluctuating pain are occasional attacks of more severe pain.  A small percentage of individuals with hemicrania continua have bilateral pain, or pain on both sides of the head.  A headache is considered hemicrania continua if the person has had a one-sided daily or continuous headache of moderate intensity with occasional short, piercing head pain for more than 3 months without shifting sides or pain-free periods.  The headache must also be completely responsive to treatment with the non-steroidal anti-inflammatory drug drug indomethacin.  It must have at least one of the following symptoms:  eye redness and/or tearing, nasal congestion and/or runny nose, ptosis (drooping eyelid) and miosis (contracture of the iris).  Occasionally, individuals will also have forehead sweating and migraine symptoms, such as throbbing pain, nausea and/or vomiting, or sensitivity to light and sound.  The disorder has two forms: chronic, with daily headaches, and remitting, in which headaches may occur for a period as long as 6 months and are followed by a pain-free period of weeks to months until the pain returns. Most patients experience attacks of increased pain three to five times per 24-hour cycle. This disorder is more common in women than in men. Physical exertion and alcohol use may increase the severity of headache pain in some patients. The cause of this disorder is unknown.

Is there any treatment?

Indomethacin provides rapid relief from symptoms. Patients must take between 25 and 300 milligrams of indomethacin daily and indefinitely to decrease symptoms.  Some individuals may need to take acid-suppression medicine due to a gastrointestinal side effect.  For those who cannot tolerate the side effects, another NSAID, celecoxib, has been shown to have less complications and can be prescribed.  Amitriptyline and other tricyclic antidepressants are also effective in some individuals with hemicrania continua as a preventative treatment.

What is the prognosis?

Individuals may obtain complete to near-complete relief of symptoms with proper medical attention and daily medication. Some people may not be able to tolerate long-term use of indomethacin and may have to rely on less effective NSAIDs.

What research is being done?

The National Institute of Neurological Disorders and Stroke (NINDS) and other institutes of the National Institutes of Health (NIH) support research related to hemicrania continua through grants to medical research institutions across the country. Much of this research focuses on understanding hemicrania continua in order to finding better ways to prevent, treat, and ultimately cure the disorder.

NIH Patient Recruitment for Hemicrania Continua Clinical Trials

Organizations

Column1 Column2
American Headache Society Committee for Headache Education (ACHE)
19 Mantua Road
Mt. Royal, NJ   08061
achehq@talley.com
http://www.achenet.org
Tel: 856-423-0043
Fax: 856-423-0082

National Headache Foundation
820 N. Orleans
Suite 411
Chicago, IL   60610-3132
info@headaches.org
http://www.headaches.org
Tel: 312-274-2650 888-NHF-5552 (643-5552)
Fax: 312-640-9049

Related NINDS Publications and Information
  • Headache: Hope Through Research
    Information about headaches, including migraines, compiled by the National Institute of Neurological Disorders and Stroke (NINDS).


Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892



NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.

All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.

Last updated April 16, 2014